Editor’s note: This is a developing news story. Please check back soon for updates.
NCX 470 0.1%, a novel nitric oxide-donating bimatoprost eye drop, achieved its primary endpoint in the phase 3 Denali clinical trial, according to a press release from Nicox.
The randomized, multiregional, double-masked, parallel group trial enrolled 696 patients with open-angle glaucoma or ocular hypertension at 90 sites in the U.S. and China. Efficacy and safety of NCX 470 were compared with latanoprost ophthalmic solution 0.005%, the standard of care. The primary endpoint was noninferiority of NCX 470